Age-less or Overhyped? The Sixty-Year Cerebrolysin Puzzle | The Age-Less Top 20 Peptides

Episode summary

Cerebrolysin is a peptide preparation with a strange résumé: developed in Austria more than sixty years ago, approved in nearly fifty countries for stroke, traumatic brain injury, and dementia, put through hundreds of clinical trials — and yet still surrounded by a genuinely unresolved question about whether it works. In this episode we unpack what it actually is (not a single peptide, but a standardized mixture of amino acids and small fragments made by enzymatically digesting pig brain tissue), the one clever idea at its core (fragments small enough to slip across the blood-brain barrier and mimic the brain's own neurotrophic factors like BDNF and NGF), and the crucial gap between an effect in a lab dish and a real benefit in a human being.

Then we get to the part the marketing skips. A 2023 systematic review found Cerebrolysin likely offers no benefit for survival in acute ischemic stroke and may even raise the rate of serious adverse events — and much of the supportive research has been funded by the manufacturer. We also cover the uncomfortable reality behind the vials sold online: it's not FDA-approved in the US, and the "research use only" label is a legal workaround for shipping an unregulated injectable with no purity or sterility guarantees. The takeaway is neither hype nor dismissal — Cerebrolysin is a genuinely interesting compound aimed at a real target, but the honest evidence says it's worth watching, not worth self-experimenting on with a needle. As always: not medical advice, and a real conversation for a licensed physician.